Inicio
Detalle del título uniforme
Transplantation Proceedings
Tipo de obra :
Autre
Naturaleza de la obra :
Oeuvre
|
Documentos disponibles con este título uniforme (6)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaHistoplasmosis in renal transplant patients in an endemic area at a reference hospital in Medellin, Colombia / John Fredy Nieto Ríos ; Lina Maria Serna Higuita ; Carlos Ernesto Guzmán Luna ; Catalina Ocampo Kohn ; Arbey Aristizabal Álzate ; Isabel Cristina Ramírez Sánchez ; Catalina Vélez Echeverri ; Juan José Vanegas Ruiz ; John Jairo Zuleta Tobón ; Gustavo Adolfo Zuluaga Valencia
Título : Histoplasmosis in renal transplant patients in an endemic area at a reference hospital in Medellin, Colombia Tipo de documento : documento electrónico Autores : John Fredy Nieto Ríos, ; Lina Maria Serna Higuita, ; Carlos Ernesto Guzmán Luna, ; Catalina Ocampo Kohn, ; Arbey Aristizabal Álzate, ; Isabel Cristina Ramírez Sánchez, ; Catalina Vélez Echeverri, ; Juan José Vanegas Ruiz, ; John Jairo Zuleta Tobón, ; Gustavo Adolfo Zuluaga Valencia, Fecha de publicación : 2014 Títulos uniformes : Transplantation Proceedings Idioma : Inglés (eng) Resumen : Background: Histoplasmosis is an uncommon systemic fungal infection, but it is potentially fatal in immunosuppressed populations. In Latin America, which is considered an endemic area for this mycosis, there have been no published reports regarding the incidence, clinical presentation, morbidity, and mortality of histoplasmosis in renal transplant patients. The objective of this study was to describe cases of histoplasmosis in renal transplant patients treated at the Pablo Tobon Uribe Hospital (Medellin, Colombia) between 2006 and 2013. Methods: This is a descriptive, retrospective study. Results: The incidence of histoplasmosis in our renal transplant population was 1.1%. The ages of the 9 patients (4 men and 5 women) ranged between 27 and 59 years. In 2 of these patients, histoplasmosis appeared during the first year after transplantation. At the time of transplantation, 66% of patients received induction with alemtuzumab; 88% had a prior rejection episode and required increased immunosuppressive medication; 88% had renal graft dysfunction with creatinine levels >1.5 mg/dL; and the primary clinical presentation was disseminated histoplasmosis followed by the pulmonary form of the disease. Diagnoses were performed by histology in 6 patients, blood culture in 2 patients, and antigenuria in 1 patient. Three patients required treatment with amphotericin B for the severity of their infection, and 2 of these patients died before receiving the cumulative dose of amphotericin B. The 7 remaining patients received itraconazole for 12 months and had a successful treatment response. Regarding complications, 2 patients had hemophagocytic syndrome. At the 1-year follow-up appointment, renal function remained stable in all patients, and no patients had acute rejection or required renal replacement therapy. Thus, the overall mortality rate observed was 22.2%. Conclusions: In this series, histoplasmosis in renal transplant patients presented as an aggressive opportunistic infection with a higher incidence than that previously reported in the literature. The following risk factors have been associated with histoplasmosis: renal graft dysfunction, previous acute rejection, immunosuppression with tacrolimus-mycophenolate, and induction with alemtuzumab. The clinical presentation of histoplasmosis was nonspecific, which complicated disease diagnosis, and the treatment regimens were highly toxic and associated with significant morbidity and mortality rates. Mención de responsabilidad : J F Nieto-Ríos, L M Serna-Higuita, C E Guzman-Luna, C Ocampo-Kohn, A Aristizabal-Alzate, I Ramírez, C Velez-Echeverri, J J Vanegas-Ruiz, J J Zuleta, G A Zuluaga-Valencia Referencia : Transplant Proc. 2014 Nov;46(9):3004-9. DOI (Digital Object Identifier) : 10.1016/j.transproceed.2014.06.060 PMID : 25420811 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(14)00499-0 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4547 Histoplasmosis in renal transplant patients in an endemic area at a reference hospital in Medellin, Colombia [documento electrónico] / John Fredy Nieto Ríos, ; Lina Maria Serna Higuita, ; Carlos Ernesto Guzmán Luna, ; Catalina Ocampo Kohn, ; Arbey Aristizabal Álzate, ; Isabel Cristina Ramírez Sánchez, ; Catalina Vélez Echeverri, ; Juan José Vanegas Ruiz, ; John Jairo Zuleta Tobón, ; Gustavo Adolfo Zuluaga Valencia, . - 2014.
Obra : Transplantation Proceedings
Idioma : Inglés (eng)
Resumen : Background: Histoplasmosis is an uncommon systemic fungal infection, but it is potentially fatal in immunosuppressed populations. In Latin America, which is considered an endemic area for this mycosis, there have been no published reports regarding the incidence, clinical presentation, morbidity, and mortality of histoplasmosis in renal transplant patients. The objective of this study was to describe cases of histoplasmosis in renal transplant patients treated at the Pablo Tobon Uribe Hospital (Medellin, Colombia) between 2006 and 2013. Methods: This is a descriptive, retrospective study. Results: The incidence of histoplasmosis in our renal transplant population was 1.1%. The ages of the 9 patients (4 men and 5 women) ranged between 27 and 59 years. In 2 of these patients, histoplasmosis appeared during the first year after transplantation. At the time of transplantation, 66% of patients received induction with alemtuzumab; 88% had a prior rejection episode and required increased immunosuppressive medication; 88% had renal graft dysfunction with creatinine levels >1.5 mg/dL; and the primary clinical presentation was disseminated histoplasmosis followed by the pulmonary form of the disease. Diagnoses were performed by histology in 6 patients, blood culture in 2 patients, and antigenuria in 1 patient. Three patients required treatment with amphotericin B for the severity of their infection, and 2 of these patients died before receiving the cumulative dose of amphotericin B. The 7 remaining patients received itraconazole for 12 months and had a successful treatment response. Regarding complications, 2 patients had hemophagocytic syndrome. At the 1-year follow-up appointment, renal function remained stable in all patients, and no patients had acute rejection or required renal replacement therapy. Thus, the overall mortality rate observed was 22.2%. Conclusions: In this series, histoplasmosis in renal transplant patients presented as an aggressive opportunistic infection with a higher incidence than that previously reported in the literature. The following risk factors have been associated with histoplasmosis: renal graft dysfunction, previous acute rejection, immunosuppression with tacrolimus-mycophenolate, and induction with alemtuzumab. The clinical presentation of histoplasmosis was nonspecific, which complicated disease diagnosis, and the treatment regimens were highly toxic and associated with significant morbidity and mortality rates. Mención de responsabilidad : J F Nieto-Ríos, L M Serna-Higuita, C E Guzman-Luna, C Ocampo-Kohn, A Aristizabal-Alzate, I Ramírez, C Velez-Echeverri, J J Vanegas-Ruiz, J J Zuleta, G A Zuluaga-Valencia Referencia : Transplant Proc. 2014 Nov;46(9):3004-9. DOI (Digital Object Identifier) : 10.1016/j.transproceed.2014.06.060 PMID : 25420811 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(14)00499-0 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4547 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001044 AC-2014-115 Archivo digital Producción Científica Artículos científicos Disponible
Título : Incidence and risk factors for cytomegalovirus disease in a Colombian cohort of kidney transplant recipients Tipo de documento : documento electrónico Autores : Fabián Alberto Jaimes Barragán, Fecha de publicación : 2014 Títulos uniformes : Transplantation Proceedings Idioma : Inglés (eng) Resumen : Incidence and risk factors for cytomegalovirus (CMV) disease in a Colombian cohort of kidney transplant recipients. CMV infection and disease are important causes of morbidity and mortality in kidney transplant recipients, and its prevalence varies with economic, geographic, and ethnic factors. Among 1620 records from a Colombian reference center, CMV immunoglobulin (Ig)G seroprevalence was found to be 90.9% among recipients and 90.2% among donors. In 86% (n = 264) of the cases, CMV disease occurred during the first 6 months after the transplantation, and the most frequent clinical presentation was CMV syndrome, followed by gastrointestinal disease. The following parameters were independent predictors of CMV disease: serological status of D+/R+ (hazard ratio [HR], 1.64; 95% confidence interval [CI], 1.03–2.63) and D+/R− (HR, 2.72; 95% CI, 1.49–4.93), age of the recipient (HR, 1.02; 95% CI, 1.01–1.03), and receiving more than 30 mg of prednisolone by the end of the first month after transplantation (HR, 1.59; 95% CI, 1.22–2.07). Acyclovir prophylaxis or other antiviral agents significantly decreased the risk of disease (HR, 0.41; 95% CI, 0.29–0.58 and HR, 0.34; 95% CI, 0.20–0.58, respectively). In conclusion, we found a high prevalence of CMV infection in a cohort of Latin American transplant recipients. In accord with findings from other regions, serological status is the main risk factor, prophylaxis with acyclovir is effective, and induction with alemtuzumab does not increase the risk of CMV disease. Mención de responsabilidad : J Díaz, J Henao, J Rodelo, A García, M Arbeláez, F Jaimes Referencia : Transplant Proc. 2014 Jan-Feb;46(1):160-6. DOI (Digital Object Identifier) : 10.1016/j.transproceed.2013.07.070 PMID : 24507044 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(13)01094-4 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3799 Incidence and risk factors for cytomegalovirus disease in a Colombian cohort of kidney transplant recipients [documento electrónico] / Fabián Alberto Jaimes Barragán, . - 2014.
Obra : Transplantation Proceedings
Idioma : Inglés (eng)
Resumen : Incidence and risk factors for cytomegalovirus (CMV) disease in a Colombian cohort of kidney transplant recipients. CMV infection and disease are important causes of morbidity and mortality in kidney transplant recipients, and its prevalence varies with economic, geographic, and ethnic factors. Among 1620 records from a Colombian reference center, CMV immunoglobulin (Ig)G seroprevalence was found to be 90.9% among recipients and 90.2% among donors. In 86% (n = 264) of the cases, CMV disease occurred during the first 6 months after the transplantation, and the most frequent clinical presentation was CMV syndrome, followed by gastrointestinal disease. The following parameters were independent predictors of CMV disease: serological status of D+/R+ (hazard ratio [HR], 1.64; 95% confidence interval [CI], 1.03–2.63) and D+/R− (HR, 2.72; 95% CI, 1.49–4.93), age of the recipient (HR, 1.02; 95% CI, 1.01–1.03), and receiving more than 30 mg of prednisolone by the end of the first month after transplantation (HR, 1.59; 95% CI, 1.22–2.07). Acyclovir prophylaxis or other antiviral agents significantly decreased the risk of disease (HR, 0.41; 95% CI, 0.29–0.58 and HR, 0.34; 95% CI, 0.20–0.58, respectively). In conclusion, we found a high prevalence of CMV infection in a cohort of Latin American transplant recipients. In accord with findings from other regions, serological status is the main risk factor, prophylaxis with acyclovir is effective, and induction with alemtuzumab does not increase the risk of CMV disease. Mención de responsabilidad : J Díaz, J Henao, J Rodelo, A García, M Arbeláez, F Jaimes Referencia : Transplant Proc. 2014 Jan-Feb;46(1):160-6. DOI (Digital Object Identifier) : 10.1016/j.transproceed.2013.07.070 PMID : 24507044 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(13)01094-4 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3799 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000374 AC-2014-040 Archivo digital Producción Científica Artículos científicos Disponible
Título : Preservation solutions for liver transplantation in adults: celsior versus custodiol: a systematic review and meta-analysis with an indirect comparison of randomized trials Tipo de documento : documento electrónico Autores : Gloria Lucía Lema Zuluaga, ; Ramón Eduardo Serna Agudelo, ; John Jairo Zuleta Tobón, Fecha de publicación : 2013 Títulos uniformes : Transplantation Proceedings Idioma : Inglés (eng) Resumen : Background: The University of Wisconsin (UW) solution has been recognized as the gold standard for liver preservation; however, it possesses some limitations, and other solutions exist for organ preservation. The aim of this study was to compare the liver functions of transplanted grafts that had been stored in Celsior and Custodiol solutions. Methods: We searched the MEDLINE, EMBASE, LILACS, Cochrane Central Register of Controlled Trials, and SCIELO databases. We included randomized and quasirandomized, controlled trials that compared the efficacy and safety of Celsior and Custodiol with UW solution for liver preservation in adults. The factors that were considered for analysis were their impacts on primary dysfunction (primary nonfunction and initial poor function), ischemic-type biliary lesions, and patient and graft survival rates. Because of the lack of direct evidence, an indirect comparison of Celsior and Custodiol was calculated. Results: We identified 3 randomized controlled trials and 1 quasi-randomized, controlled trial to pool in a meta-analysis of Celsior versus UW solutions. The number of episodes of primary dysfunction was lower in the Celsior group (7.4%) than in the UW group (9.8%), but the difference was not significant (relative risk [RR], 0.68; 95% confidence interval [CI], 0.22–1.97). Two randomized controlled trials compared Custodiol and Wisconsin solutions were identified. The number of episodes of primary dysfunction was also lower in the Custodiol group (3.0%) compared with the Wisconsin group (8.4%), but the difference was not significant (RR, 0.36; 95% CI, 0.08 –1.70). An indirect comparison using data from the main analysis revealed no difference between the Celsior and Custodiol solutions (RR, 1.88; 95% CI, 0.57– 6.16). Conclusion: The Celsior and Custodiol solutions performed similarly to UW solution as preservation solutions in liver transplantation clinical settings. Mención de responsabilidad : G L Lema Zuluaga, R E Serna Agudelo, J J Zuleta Tobón Referencia : Transplant Proc. 2013 Jan-Feb;45(1):25-32. DOI (Digital Object Identifier) : 10.1016/j.transproceed.2012.02.031 PMID : 23267794 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(12)00682-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3681 Preservation solutions for liver transplantation in adults: celsior versus custodiol: a systematic review and meta-analysis with an indirect comparison of randomized trials [documento electrónico] / Gloria Lucía Lema Zuluaga, ; Ramón Eduardo Serna Agudelo, ; John Jairo Zuleta Tobón, . - 2013.
Obra : Transplantation Proceedings
Idioma : Inglés (eng)
Resumen : Background: The University of Wisconsin (UW) solution has been recognized as the gold standard for liver preservation; however, it possesses some limitations, and other solutions exist for organ preservation. The aim of this study was to compare the liver functions of transplanted grafts that had been stored in Celsior and Custodiol solutions. Methods: We searched the MEDLINE, EMBASE, LILACS, Cochrane Central Register of Controlled Trials, and SCIELO databases. We included randomized and quasirandomized, controlled trials that compared the efficacy and safety of Celsior and Custodiol with UW solution for liver preservation in adults. The factors that were considered for analysis were their impacts on primary dysfunction (primary nonfunction and initial poor function), ischemic-type biliary lesions, and patient and graft survival rates. Because of the lack of direct evidence, an indirect comparison of Celsior and Custodiol was calculated. Results: We identified 3 randomized controlled trials and 1 quasi-randomized, controlled trial to pool in a meta-analysis of Celsior versus UW solutions. The number of episodes of primary dysfunction was lower in the Celsior group (7.4%) than in the UW group (9.8%), but the difference was not significant (relative risk [RR], 0.68; 95% confidence interval [CI], 0.22–1.97). Two randomized controlled trials compared Custodiol and Wisconsin solutions were identified. The number of episodes of primary dysfunction was also lower in the Custodiol group (3.0%) compared with the Wisconsin group (8.4%), but the difference was not significant (RR, 0.36; 95% CI, 0.08 –1.70). An indirect comparison using data from the main analysis revealed no difference between the Celsior and Custodiol solutions (RR, 1.88; 95% CI, 0.57– 6.16). Conclusion: The Celsior and Custodiol solutions performed similarly to UW solution as preservation solutions in liver transplantation clinical settings. Mención de responsabilidad : G L Lema Zuluaga, R E Serna Agudelo, J J Zuleta Tobón Referencia : Transplant Proc. 2013 Jan-Feb;45(1):25-32. DOI (Digital Object Identifier) : 10.1016/j.transproceed.2012.02.031 PMID : 23267794 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(12)00682-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3681 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000254 AC-2013-022 Archivo digital Producción Científica Artículos científicos Disponible
Título : Survival of renal transplantation patients older than 60 years: a single-center experience Tipo de documento : documento electrónico Autores : John Fredy Nieto Ríos, ; Lina Maria Serna Higuita, Fecha de publicación : 2013 Títulos uniformes : Transplantation Proceedings Idioma : Inglés (eng) Resumen : Background: Elderly patients are the fastest growing population requiring renal replacement therapy. It has been stated that renal transplantation may be the best treatment option for these patients. However, it has been observed that older patients have a higher mortality rate than those who are younger. Yet the factors that determine post-transplantation outcomes in this population remain poorly defined. The aims of this study were to evaluate the graft and patient survival in kidney transplant recipients who are older than 60 years of age to identify relevant predictive factors. Methods: In this population-based retrospective cohort study of 201 kidney transplantations performed in elderly patients from January 2002 throughout June 2009, we estimated the 1-,3-,and 5-year patients and graft survival rates. We also evaluated the complications and the predictors of poor outcomes. Survival times were analyzed using the Kaplan–Meier method and survival differences assessed with Mantel-Cox log rank-test. We performed a Cox proportional hazards regression models to evaluate the impact of baseline and treatment characteristics on patient and graft survival. Results: Graft and patient survival rates at 1, 3, and 5 years were 76.4%, 71.3%, and 54.3%, and 78.2%, 73.8%, and 56.4%, respectively. Graft survival rates censored for patient death with a functioning graft were 93.1, 92.1, and 89%. Patient survival rates differed between diabetic and nondiabetic subjects at 1, 3 and 5 years (69.5% versus 83.6%; 59.8% versus 72.3%; 43.6% versus 65.7%; P = .008). On multivariate analysis, the factors associated with patients survival were diabetes mellitus (hazard ratio [HR] 2.058, 95% confidence interval [CI] 1.173–3.611, P = .012) and the 1-month serum creatinine value was > 1.6 mg/dL (HR 2.108 for each point increase, 95% CI 1.521–2.921, P = .000). Furthermore, there was an insignificant trend forward an association between active or past smoker and lower patient survival (HR 1.689, 95% CI 0.937–3.043, P = .08). The main causes of graft loss were patient death (79.5%). acute rejection (6.8%), and chronic allograft nephropathy (5.5%). Conclusion: Renal transplantation can be performed safely and with acceptable outcomes in elderly patients after appropriate clinical evaluation. The grafts show excellent survival albeit that deaths with a functional graft continue to be an important issue. Mención de responsabilidad : J R Rodelo, J F Nieto-Ríos, L M Serna-Higuita, J E Henao, A García, A C Reino, J C Tobón, M Arbeláez Referencia : Transplant Proc. 2013 May;45(4):1402-9. DOI (Digital Object Identifier) : 10.1016/j.transproceed.2012.10.053 PMID : 23726583 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(12)01403-0 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3719 Survival of renal transplantation patients older than 60 years: a single-center experience [documento electrónico] / John Fredy Nieto Ríos, ; Lina Maria Serna Higuita, . - 2013.
Obra : Transplantation Proceedings
Idioma : Inglés (eng)
Resumen : Background: Elderly patients are the fastest growing population requiring renal replacement therapy. It has been stated that renal transplantation may be the best treatment option for these patients. However, it has been observed that older patients have a higher mortality rate than those who are younger. Yet the factors that determine post-transplantation outcomes in this population remain poorly defined. The aims of this study were to evaluate the graft and patient survival in kidney transplant recipients who are older than 60 years of age to identify relevant predictive factors. Methods: In this population-based retrospective cohort study of 201 kidney transplantations performed in elderly patients from January 2002 throughout June 2009, we estimated the 1-,3-,and 5-year patients and graft survival rates. We also evaluated the complications and the predictors of poor outcomes. Survival times were analyzed using the Kaplan–Meier method and survival differences assessed with Mantel-Cox log rank-test. We performed a Cox proportional hazards regression models to evaluate the impact of baseline and treatment characteristics on patient and graft survival. Results: Graft and patient survival rates at 1, 3, and 5 years were 76.4%, 71.3%, and 54.3%, and 78.2%, 73.8%, and 56.4%, respectively. Graft survival rates censored for patient death with a functioning graft were 93.1, 92.1, and 89%. Patient survival rates differed between diabetic and nondiabetic subjects at 1, 3 and 5 years (69.5% versus 83.6%; 59.8% versus 72.3%; 43.6% versus 65.7%; P = .008). On multivariate analysis, the factors associated with patients survival were diabetes mellitus (hazard ratio [HR] 2.058, 95% confidence interval [CI] 1.173–3.611, P = .012) and the 1-month serum creatinine value was > 1.6 mg/dL (HR 2.108 for each point increase, 95% CI 1.521–2.921, P = .000). Furthermore, there was an insignificant trend forward an association between active or past smoker and lower patient survival (HR 1.689, 95% CI 0.937–3.043, P = .08). The main causes of graft loss were patient death (79.5%). acute rejection (6.8%), and chronic allograft nephropathy (5.5%). Conclusion: Renal transplantation can be performed safely and with acceptable outcomes in elderly patients after appropriate clinical evaluation. The grafts show excellent survival albeit that deaths with a functional graft continue to be an important issue. Mención de responsabilidad : J R Rodelo, J F Nieto-Ríos, L M Serna-Higuita, J E Henao, A García, A C Reino, J C Tobón, M Arbeláez Referencia : Transplant Proc. 2013 May;45(4):1402-9. DOI (Digital Object Identifier) : 10.1016/j.transproceed.2012.10.053 PMID : 23726583 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(12)01403-0 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3719 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000292 AC-2013-060 Archivo digital Producción Científica Artículos científicos Disponible
Título : Clinical description and evolution of renal transplant pediatric patients treated with alemtuzumab Tipo de documento : documento electrónico Autores : Catalina Vélez Echeverri, ; Gustavo Adolfo Zuluaga Valencia, ; Catalina Ocampo Kohn, ; Arbey Aristizabal Álzate, ; Lina Maria Serna Higuita, ; John Jairo Zuleta Tobón, ; Juan José Vanegas Ruiz, Fecha de publicación : 2011 Títulos uniformes : Transplantation Proceedings Idioma : Francés (fre) Idioma original : Inglés (eng) Resumen : Background: Renal transplantation is the most effective treatment for children with end-stage renal disease. Recent work suggests that induction with alemtuzumab in the pediatric population permits the use of lower doses of maintenance immunosuppressive therapy. In addition, it has a low cost compared with other induction therapies. Objective: To conduct a clinical description of pediatric renal transplant patients comparing induction protocols to evaluate graft and patient survival, infections complications, and lymphoproliferative diseases. Materials and Methods. This descriptive and retrospective study, of evaluated pediatric renal transplant patients between 2006 and 2010. Results: The agents for induction therapy were: alemtuzumab (61.5%), daclizumab (19.25%), and thymoglobulin (19.25%). Graft survival was better among the alemtuzumab group (87.5%) compared with the other two induction therapies (80%). The frequency of acute rejection episodes during the first year posttransplantation as well as chronic rejection was lower among the alemtuzumab group. Cytomegalovirus infection was noted in 30% of patients with greater frequency among those induced with alemtuzumab. Conclusion: Induction therapy with alemtuzumab was safe in a pediatric population not predisposing to a greater risk of acute or chronic rejection. Except for a greater incidence of Cytomegalovirus, there was no difference in other complications. Mención de responsabilidad : C Velez, G Zuluaga, C Ocampo, A Aristizabal, L M Serna, A K Serrano Gayubo, J A Florez, J J Zuleta, J J Vanegas Ruiz Referencia : Transplant Proc. 2011 Nov;43(9):3350-4. DOI (Digital Object Identifier) : 10.1016/j.transproceed.2011.09.101 PMID : 22099794 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(11)01380-7 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3583 Clinical description and evolution of renal transplant pediatric patients treated with alemtuzumab [documento electrónico] / Catalina Vélez Echeverri, ; Gustavo Adolfo Zuluaga Valencia, ; Catalina Ocampo Kohn, ; Arbey Aristizabal Álzate, ; Lina Maria Serna Higuita, ; John Jairo Zuleta Tobón, ; Juan José Vanegas Ruiz, . - 2011.
Obra : Transplantation Proceedings
Idioma : Francés (fre) Idioma original : Inglés (eng)
Resumen : Background: Renal transplantation is the most effective treatment for children with end-stage renal disease. Recent work suggests that induction with alemtuzumab in the pediatric population permits the use of lower doses of maintenance immunosuppressive therapy. In addition, it has a low cost compared with other induction therapies. Objective: To conduct a clinical description of pediatric renal transplant patients comparing induction protocols to evaluate graft and patient survival, infections complications, and lymphoproliferative diseases. Materials and Methods. This descriptive and retrospective study, of evaluated pediatric renal transplant patients between 2006 and 2010. Results: The agents for induction therapy were: alemtuzumab (61.5%), daclizumab (19.25%), and thymoglobulin (19.25%). Graft survival was better among the alemtuzumab group (87.5%) compared with the other two induction therapies (80%). The frequency of acute rejection episodes during the first year posttransplantation as well as chronic rejection was lower among the alemtuzumab group. Cytomegalovirus infection was noted in 30% of patients with greater frequency among those induced with alemtuzumab. Conclusion: Induction therapy with alemtuzumab was safe in a pediatric population not predisposing to a greater risk of acute or chronic rejection. Except for a greater incidence of Cytomegalovirus, there was no difference in other complications. Mención de responsabilidad : C Velez, G Zuluaga, C Ocampo, A Aristizabal, L M Serna, A K Serrano Gayubo, J A Florez, J J Zuleta, J J Vanegas Ruiz Referencia : Transplant Proc. 2011 Nov;43(9):3350-4. DOI (Digital Object Identifier) : 10.1016/j.transproceed.2011.09.101 PMID : 22099794 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(11)01380-7 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3583 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000153 AC-2011-038 Archivo digital Producción Científica Artículos científicos Disponible Permalink
